APACHE II (mean±SD) |
22.17±7.61 |
25.78±6.542 |
0.04 |
Duration of hospitalization before COL therapy, median (min-max) |
17
(5-43) |
18 (3-101) |
0.930 |
Initial serum urea (mg/dL) median (min-max) |
36 (20-99) |
52 (16-125) |
0.081 |
Initial serum creatinine (mg/dL) (mean±SD) |
0.74±0.191 |
0.78±0.204 |
0.424 |
End-treatment serum urea (mg/dL) median (min-max) |
85.5 (36-266) |
117.5 (43-295) |
0.089 |
End-treatment serum creatinine (mg/dL) median (min-max) |
2.34
(0.73-5.68) |
2.56 (1-8) |
0.970 |
Total colistin day, median (min-max) |
14 (5-22) |
10 (4-23) |
0.123 |
Colistin toxicity day, median (min-max) |
7.5 (2-19) |
5 (2-18) |
0.236 |
Underlying diseases, n (%)
Chronic obstructive pulmonary disease
Diabetes mellitus
Coronary artery disease
Cardiac failure
Immunosupression
Solid organ malignancy
|
8 (44.4)
7 (38.9)
3 (16.7)
1 (5.6)
5 (27.8)
0 (0.0)
|
53 (60.2)
23 (26.1)
27 (30.7)
23 (26.1)
2 (2.3)
3 (3.4)
|
0.217
0.274
0.229
0.067
0.001
1.00
|
Vasopressor agent use, n (%) |
5 (27.8) |
55 (62.5) |
0.009 |
Concomitant nephrotoxic agent use, n (%) |
13 (72.2) |
63 (71.6) |
0.957 |
Need for hemodialysis, n (%) |
1 (5.6) |
4 (4.5) |
1.00 |
14-day mortality, n (%) |
4 (22.2) |
46 (52.3) |
0.02 |
28-day mortality, n (%) |
6 (40) |
31 (73.8) |
0.019 |
Overall mortality, n (%) |
14 (77.8) |
84 (95.5) |
0.027 |